I am a faculty member in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center and a member of the graduate faculty at the State University of New York (SUNY) at Buffalo. I have developed a functional genomics research program that investigates the genetics and epigenetics of bladder and prostate cancers to identify new tumor vulnerabilities and rational therapeutic strategies. My group's basic and translational research focuses on novel diagnostic and prognostic biomarkers via unbiased approaches such as whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA sequencing (RNAseq), and DNA methylation profiling of well-curated and annotated clinical specimens of bladder and prostate cancer.
Ramakrishnan S, Granger V, Rak M, Hu Q et al Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death and Differentiation 2019 Jan 28. doi: 10.1038/s41418-019-0278-9
Aquila L, Ohm J, Woloszynska-Read A. The role of STAG2 in bladder cancer. Pharmacol Res. 2018 May;131:143-149. doi: 10.1016/j.phrs.2018.02.025. Epub 2018 Mar 1.
Ramakrishnan S, Huss W, Foster B, Ohm J, Wang J, Azabdaftari G, Eng K, Woloszynska-Read A. Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice. Am J Clin Exp Urol. 2018 Jun 15;6(3):138-148.
Ramakrishnan S, Hu Q, Krishnan N et al Decitabine, a DNA demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death and Disease. 2017 Dec 14;8(12):3217. PMCID: PMC5870579
Huang FW, Mosquera JM, Garofalo A et al Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery. 2017 Sep;7(9):973-983. PMCID: PMC5836784